Electrocardiographic criteria for LVH identified hypertensive patients with a >70% prevalence of anatomic LVH (OR 11.4 vs employed hypertensives), allowing accurate identification of high-risk status.
Cross-Sectional (n=1,612)
Does electrocardiographic LVH accurately identify anatomic echocardiographic LVH in hypertensive patients?
The ECG criteria used in the LIFE trial accurately identify a high prevalence (>70%) of anatomic LVH in hypertensive patients, validating its use for risk stratification.
Effect estimate: OR 11.4
p-value: p=<0.001
AIM: To assess the prevalence of echocardiographic left ventricular hypertrophy (LVH) and concentric remodeling in hypertensive patients with electrocardiographic (ECG)-LVH and to estimate the cost-effectiveness of echocardiography and ECG for detection of LVH. DESIGN: Echocardiographic LV measurements and the prevalence of abnormal LV geometric patterns were compared between 964 hypertensive patients with ECG-LVH (Cornell voltage-duration product > 2440 and/or SV1 +/- RV5-6 > 38 mm) participating in the LIFE trial and groups of 282 employed hypertensives and 366 apparently normal adults. RESULTS: Among both women and men, stepwise increases from reference subjects to employed hypertensives to LIFE patients were observed for LV wall thicknesses, chamber size and mass. Mean LV mass/body surface area (BSA) and LV mass/height(2.7) were substantially larger in LIFE patients than normal adults among women (113 vs 69 g/m2 and 55 vs 32 g/m(2.7), p 70% prevalence of anatomic LVH, allowing accurate identification of high-risk status by this commonly used technique.
Devereux et al. (Mon,) conducted a cross-sectional in Hypertension with electrocardiographic left ventricular hypertrophy (n=1,612). Electrocardiographic left ventricular hypertrophy (ECG-LVH) vs. Employed hypertensives and apparently normal adults was evaluated on Prevalence of echocardiographic left ventricular hypertrophy (LVH) (OR 11.4, p=<0.001). Electrocardiographic criteria for LVH identified hypertensive patients with a >70% prevalence of anatomic LVH (OR 11.4 vs employed hypertensives), allowing accurate identification of high-risk status.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: